Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Ronald F. Van Vollenhoven, Paul Emery, Clifton O. Bingham, Edward C. Keystone, Roy M. Fleischmann, Daniel E. Furst, Nicola Tyson, Neil Collinson, Patricia B. Lehane

Research output: Contribution to journal › Article › peer-review

217 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds